The antimicrobial agent C31G is effective for therapy for HSV-1 ocular keratitis in the rabbit eye model.

[1]  D. Gilden.  Faculty Opinions recommendation of A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. , 2015 .

[2]  Yu Liang,et al.  A Novel Selective LSD1/KDM1A Inhibitor Epigenetically Blocks Herpes Simplex Virus Lytic Replication and Reactivation from Latency , 2013, mBio.

[3]  C. Brandt,et al.  A cationic peptide, TAT-Cd°, inhibits herpes simplex virus type 1 ocular infection in vivo. , 2013, Investigative ophthalmology & visual science.

[4]  Jesse H. Arbuckle,et al.  Targeting the JMJD2 Histone Demethylases to Epigenetically Control Herpesvirus Infection and Reactivation from Latency , 2013, Science Translational Medicine.

[5]  K. Morris,et al.  Snapshots: chromatin control of viral infection. , 2013, Virology.

[6]  T. Kristie.  The rise of epigenetic targets for the development of novel antivirals , 2012, Expert review of anti-infective therapy.

[7]  P. Delvenne,et al.  Dermal Ultrastructure in Low Beighton Score Members of 17 Families with Hypermobile-Type Ehlers-Danlos Syndrome , 2012, Journal of biomedicine & biotechnology.

[8]  T. Foster,et al.  Rabbit and Mouse Models of HSV-1 Latency, Reactivation, and Recurrent Eye Diseases , 2012, Journal of biomedicine & biotechnology.

[9]  Shalini Sharma,et al.  Role of miR-132 in angiogenesis after ocular infection with herpes simplex virus. , 2012, The American journal of pathology.

[10]  C. Ishikawa,et al.  Efficacy of Bidens pilosa Extract against Herpes Simplex Virus Infection In Vitro and In Vivo , 2012, Evidence-based complementary and alternative medicine : eCAM.

[11]  T. Daikoku,et al.  Efficacy of ASP2151, a helicase-primase inhibitor, against thymidine kinase-deficient herpes simplex virus type 2 infection in vitro and in vivo. , 2012, Antiviral research.

[12]  K. Barnhart,et al.  Contraceptive Efficacy, Acceptability, and Safety of C31G and Nonoxynol-9 Spermicidal Gels: A Randomized Controlled Trial , 2010, Obstetrics and gynecology.

[13]  James M. Hill,et al.  A Human Apolipoprotein E Mimetic Peptide Effectively Inhibits HSV-1 TK-Positive and TK-Negative Acute Epithelial Keratitis in Rabbits , 2009, Current eye research.

[14]  Gyanendra Singh,et al.  Effective treatment of ocular HSK with a human apolipoprotein E mimetic peptide in a mouse eye model. , 2008, Investigative ophthalmology & visual science.

[15]  Michael R. Chernick,et al.  Pharmaceutical Statistics Using SAS® A Practical Guide , 2008, Technometrics.

[16]  T. Foster,et al.  Ocular HSV-1 Latency, Reactivation and Recurrent Disease , 2008, Seminars in ophthalmology.

[17]  A. Waring,et al.  Evaluation of a θ-Defensin in a Murine Model of Herpes Simplex Virus Type 1 Keratitis , 2007 .

[18]  A. Waring,et al.  Evaluation of a theta-defensin in a Murine model of herpes simplex virus type 1 keratitis. , 2007, Investigative ophthalmology & visual science.

[19]  S. Hillier,et al.  Vaginal and Rectal Topical Microbicide Development: Safety and Efficacy of 1.0% Savvy (C31G) in the Pigtailed Macaque , 2006, Sexually transmitted diseases.

[20]  S. Majumdar,et al.  Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations. , 2005, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[21]  Subir Ghosh,et al.  Nonparametric Analysis of Longitudinal Data in Factorial Experiments , 2003, Technometrics.

[22]  H. Bultmann,et al.  Peptides Containing Membrane-transiting Motifs Inhibit Virus Entry* , 2002, Journal of Biological Chemistry.

[23]  F. Krebs,et al.  Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate. , 1999, Antiviral research.

[24]  F. Krebs,et al.  A Broad-Spectrum Microbicide with Virucidal Activity against Sexually Transmitted Viruses , 1999, Antimicrobial Agents and Chemotherapy.

[25]  F. Krebs,et al.  Anti-viral activity of microbicides in model systems. 12th World AIDS Conference , 1998 .

[26]  J. Raulston,et al.  The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro , 1997, Antimicrobial agents and chemotherapy.

[27]  D. Malamud,et al.  Assessment of the anti-microbial agent C31G as a spermicide: comparison with nonoxynol-9. , 1996, Contraception.

[28]  A. Ayhan,et al.  A non-antibiotic antimicrobial mixture (C31G): evaluation of the antimicrobial efficiency of C31G on vaginal cultures. , 1992, Bollettino chimico farmaceutico.

[29]  D. H. Watts,et al.  Antiviral agents. , 1992, Obstetrics and gynecology clinics of North America.

[30]  S. Yankell,et al.  C31G, a new agent for oral use with potent antimicrobial and antiadherence properties , 1988, Antimicrobial Agents and Chemotherapy.

[31]  D. S. Hull,et al.  Effect of iontophoretic and topical application of antiviral agents in treatment of experimental HSV-1 keratitis in rabbits. , 1979, Investigative ophthalmology & visual science.

[32]  H. Kaufman,et al.  Clinical evaluation of trifluorothymidine in the treatment of herpes simplex corneal ulcers. , 1972, American journal of ophthalmology.

[33]  N. Sapeika,et al.  Ocular Pharmacology , 1971 .